Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson’s Disease
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background and Purpose The detection of α-synuclein in the body fluids of patients with synucleinopathy has yielded promising but inconclusive results, in part because of conformational changes of α-synuclein in response to environmental conditions. The aim of this study was to determine the feasibility of using α-synuclein as a biological marker for Parkinson’s disease (PD). Methods Twenty-three drug-naïve patients with PD (age 62.4±12.7 years, mean±SD; 11 males)and 29 age- and sex-matched neurologic control subjects (age 60.1±16.2 years; 16 males) were recruited. The levels of oligomeric and total α-synuclein in the cerebrospinal fluid (CSF) and plasma were measured using two simultaneous enzyme-linked immunosorbent assays. Results The level of α-synuclein oligomer in the CSF of PD patients was significantly higher in PD patients than in neurological controls, but other findings (plasma α-synuclein oligomer and total α-synuclein in CSF and plasma) did not differ significantly between the two groups. When the control subjects were divided into a symptomatic control group (11 patients who complained of parkinsonian symptoms and were diagnosed with hydrocephalus and drug-induced or vascular parkinsonism) and a neurologic control group (10 normal subjects and 8 patients with diabetic ophthalmoplegia), the level of α-synuclein oligomer in the CSF was still significantly higher in PD patients than in both of the control subgroups. Conclusions These findings provide further evidence for a pathogenic role of the α-synuclein oligomer and suggest that CSF levels of α-synuclein oligomer can be a reliable marker for PD.
Abstract
Background and Purpose The detection of α-synuclein in the body fluids of patients with synucleinopathy has yielded promising but inconclusive results, in part because of conformational changes of α-synuclein in response to environmental conditions. The aim of this study was to determine the feasibility of using α-synuclein as a biological marker for Parkinson’s disease (PD). Methods Twenty-three drug-naïve patients with PD (age 62.4±12.7 years, mean±SD; 11 males)and 29 age- and sex-matched neurologic control subjects (age 60.1±16.2 years; 16 males) were recruited. The levels of oligomeric and total α-synuclein in the cerebrospinal fluid (CSF) and plasma were measured using two simultaneous enzyme-linked immunosorbent assays. Results The level of α-synuclein oligomer in the CSF of PD patients was significantly higher in PD patients than in neurological controls, but other findings (plasma α-synuclein oligomer and total α-synuclein in CSF and plasma) did not differ significantly between the two groups. When the control subjects were divided into a symptomatic control group (11 patients who complained of parkinsonian symptoms and were diagnosed with hydrocephalus and drug-induced or vascular parkinsonism) and a neurologic control group (10 normal subjects and 8 patients with diabetic ophthalmoplegia), the level of α-synuclein oligomer in the CSF was still significantly higher in PD patients than in both of the control subgroups. Conclusions These findings provide further evidence for a pathogenic role of the α-synuclein oligomer and suggest that CSF levels of α-synuclein oligomer can be a reliable marker for PD.
참고문헌 (47)
- 고성범, "안산시에서의 파킨슨 증후군의 역학 조사", 대한신경과학회지, 21(5), pp.9~501 (2003), 대한신경과학회
- Twelves D, "Systematic review of incidence studies of Parkinson’s disease", Mov Disord, 18, pp.19~31 (2003)
- Gibb WR, "Accuracy in the clinical diagnosis of parkinsonian syndromes", Postgrad Med J, 64, pp.345~351 (1988)
- Gelb DJ, "Diagnostic criteria for Parkinson disease", Arch Neurol, 56, pp.33~39 (1999)
- Forno LS, "Neuropathology of Parkinson’s disease", J Neuropathol Exp Neurol, 55, pp.259~272 (1996)
- Rajput AH, "Accuracy of clinical diagnosis in parkinsonism--a prospective study", Can J Neurol Sci, 18, pp.275~278 (1991)
- Hughes AJ, "A clinicopathologic study of 100 cases of Parkinson’s disease", Arch Neurol, 50, pp.140~148 (1993)
- Tretiakoff K, "Contribution a l’etudie de l’anatomie pathologique du locus niger de Soemmering avec quelques deductions relatives a la pathogenie des troubles du tonus musculaire et de la maladie de Parkinson", 석사, pp.1919
- Fukuda T, "Immunohistochemistry of neuronal inclusions in the cerebral cortex and brain-stem in Lewy body disease", Acta Pathol Jpn, 43, pp.545~551 (1993)
- Shults CW, "Lewy bodies", Proc Natl Acad Sci U S A, 103, pp.1661~1668 (2006)
- Polymeropoulos MH, "Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease", Science, 276, pp.2045~2047 (1997)
- Singleton AB, "alpha-Synuclein locus triplication causes Parkinson’s disease", Science, 302, pp.841~ (2003)
- Miller DW, "Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication", Neurology, 62, pp.1835~1838 (2004)
- Ross OA, "Genomic investigation of alpha-synuclein multiplication and parkinsonism", Ann Neurol, 63, pp.743~750 (2008)
- Wood SJ, "Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson’s disease", J Biol Chem, 274, pp.19509~19512 (1999)
- Conway KA, "Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy", Proc Natl Acad Sci U S A, 97, pp.571~576 (2000)
- 이혜진, "Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations", JOURNAL OF BIOLOGICAL CHEMISTRY, 276(47), pp.43495~43498, AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
- Galvin JE, "Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson’s disease: a case for the selective vulnerability of the substantia nigra", Acta Neuropathol, 112, pp.115~126 (2006)
- Soto C, "Protein misfolding and neurodegeneration", Arch Neurol, 65, pp.184~189 (2008)
- Braak H, "Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen", J Neural Transm, 110, pp.517~536 (2003)
- Lee SJ, "Origins and effects of extracellular alpha-synuclein: implications in Parkinson’s disease", J Mol Neurosci, 34, pp.17~22 (2008)
- Danzer KM, "Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology", J Neurochem, 111, pp.192~203 (2009)
- 이혜진, "Intravesicular localization and exocytosis of alpha-synuclein and its aggregates", JOURNAL OF NEUROSCIENCE, 25(25), pp.6016~6024, SOC NEUROSCIENCE
- Lee HJ, "Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein", Int J Biochem Cell Biol, 40, pp.1835~1849 (2008)
- 김창연, "Controlling the mass action of ??-synuclein in Parkinson's disease", Journal of Neurochemistry, 107(2), pp.303~316, Blackwell Publishing Inc.
- Lee PH, "The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy", J Neural Transm, 113, pp.1435~1439 (2006)
- Li QX, "Plasma alpha-synuclein is decreased in subjects with Parkinson’s disease", Exp Neurol, 204, pp.583~588 (2007)
- Mollenhauer B, "Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration", Exp Neurol, 213, pp.315~325 (2008)
- Ohrfelt A, "Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders- a marker of synapse loss", Neurosci Lett, 450, pp.332~335 (2009)
- El-Agnaf OM, "Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease", FASEB J, 20, pp.419~425 (2006)
- Paleologou KE, "Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies", Brain, 132, pp.1093~1101 (2009)
- Outeiro TF, "Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies", Perspect Medicin Chem, 2, pp.41~49 (2008)
- Yuan B, "Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells", Neurosci Lett, 459, pp.16~18 (2009)
- Pandey AP, "Clustering of alpha-synuclein on supported lipid bilayers: role of anionic lipid, protein, and divalent ion concentration", Biophys J, 96, pp.540~551 (2009)
- Brown DR, "Metal binding to alpha-synuclein peptides and its contribution to toxicity", Biochem Biophys Res Commun, 380, pp.377~381 (2009)
- Outeiro TF, "Dopamine-induced conformational changes in alpha-synuclein", PLoS One, 5, pp.6906~ (2009)
- Uversky VN, "Evidence for a partially folded intermediate in alpha-synuclein fibril formation", J Biol Chem, 276, pp.10737~10744 (2001)
- Uversky VN, "A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders", J Biomol Struct Dyn, 21, pp.211~234 (2003)
- Iwai A, "The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system", Neuron, 14, pp.467~475 (1995)
- Davidson WS, "Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes", J Biol Chem, 273, pp.9443~9449 (1998)
- Li JY, "Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation", Nat Med, 14, pp.501~503 (2008)
- Kordower JH, "Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease", Nat Med, 14, pp.504~506 (2008)
- Tokuda T, "Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease", Biochem Biophys Res Commun, 349, pp.162~166 (2006)
- Yamakawa K, "Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells", Biochem Biophys Res Commun, 391, pp.129~134 (2010)
- Du HN, "A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein", Biochemistry, 42, pp.8870~8878 (2003)
- Volles MJ, "Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson’s disease", Biochemistry, 42, pp.7871~7878 (2003)
- Zhang W, "Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease", FASEB J, 19, pp.533~542 (2005)